Dr. Richard Jove Joins VGTI Florida as the New Institute Director

Dr. Richard Jove Joins VGTI Florida as the New Institute Director

VGTI FloridaCatherine E. Vorwald, 772-345-5633Executive DirectorMarketing and Business Development

The Vaccine & Gene Therapy Institute of Florida (VGTI Florida®) is pleased to announce the appointment of Richard Jove, Ph.D., as the new director of the Institute. Dr. Jove will take up his new position beginning July 1, 2013.

“Dr. Jove brings to VGTI Florida the scientific leadership, research expertise, and a translational philosophy that will bring us to the next level in terms of basic and clinical research and the related improvement of health outcomes,” said Jay Nelson, Ph.D., CEO of VGTI Florida.

As an external member of the Scientific Advisory Board for VGTI Florida, Dr. Jove has already assisted the Institute in planning its research strategy for cancer and infectious disease. “I am very excited now to become a member of the internal leadership team at VGTI Florida as their mission of `Translating Research into Health has always been a guiding principle in my own research career,” said Dr. Jove. “Having the opportunity to contribute what I have learned, and to work closely with the talented researchers and staff at VGTI Florida, will help us bring new scientific discoveries to benefit patients in the clinic.”

Richard Jove has most recently served as the director of the Beckman Research Institute at City of Hope and deputy director of its Comprehensive Cancer Center in Los Angeles County, California. His work has been focused on developing more effective and safer therapies for the treatment of cancer. One of his primary roles has been encouragement of collaboration between scientists and clinical investigators for the development of scientific discoveries into novel cancer therapies for early phase clinical trials.

Prior to joining the City of Hope Dr. Jove held various leadership positions at the Moffitt Cancer Center in Tampa, Florida, following his establishing the Molecular Oncology Program at the University of Michigan Cancer Center in Ann Arbor.

“Dr. Jove is a welcome addition to the VGTI Florida team and we all look forward to his leadership and scientific background contributing to the growth of the institute. With his global perspective and reach he is ideally suited to expand the depth and breadth on an international basis enhancing VGTI Florida’s worldwide translational research healthcare platform,” said Mel Rothberg, Chief Operating Officer of VGTI Florida.

“It’s not just about the science, more importantly it’s about the patients,” said Dr. Jove. “VGTI Florida is an Institute that is not only doing the research, but developing the therapies, and I look forward to leading the institute and the recruitment of top researchers that will expand our focus on cancer.”

VGTI Florida is an independent immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for existing and emerging infectious diseases, influenza and cancer. VGTI Florida is an independent non-profit 501(c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit . VGTI Florida® and Translating Research into Health® are Registered Trademarks of the Vaccine & Gene Therapy Institute of Florida.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.